The effect of canakinumab adjunctive treatment on symptoms and cognition in people with schizophrenia displaying elevated peripheral inflammatory markers

Trial Profile

The effect of canakinumab adjunctive treatment on symptoms and cognition in people with schizophrenia displaying elevated peripheral inflammatory markers

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CATS
  • Most Recent Events

    • 11 May 2016 Status changed from not yet recruiting to recruiting.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top